Leukos Biotech

Leukos Biotech is a bio-pharmaceutical company focused on the development of new treatments for Acute Myeloid Leukaemia and other haematological malignancies.

[Leukos Biotech @LeukosBiotech]

We are very proud to share with such great companies this space at the Institut de Recerca contra la Leucèmia Josep Carreras.

[Leukos Biotech @LeukosBiotech]

Regulatory Science to 2025 – launch of six-month public consultation | European Medicines Agency https://t.co/PzMV186WP5

[Leukos Biotech @LeukosBiotech]

We are very happy to welcome our new Lab Manager: Lise Clément-Demange.
https://t.co/2EwtPQJOoV

[Biocat @biocat_bioregio]

Ruth Risueño @LeukosBiotech és un dels casos d'èxit de #techtransfer a la #BioRegioCatalunya, avui ens ho explica a la presentació de l'#InformeBiocat

[Leukos Biotech @LeukosBiotech]

A New Biology for a New Century
https://t.co/oF2HCznum6

[Leukos Biotech @LeukosBiotech]

New article by Dr. Risueño's Lab and Leukos Biotech on the role of HTRs in MDS and CMML. https://t.co/z4gmRK7hlq

[fcarreras @fcarreras]

Leucemia, no lo olvides, vamos a por ti. Vamos a ponerte una fecha final para que todos los pacientes te sobrevivan. Necesitamos ser más contra ti. ¿Nos echas una mano? https://t.co/X9AtNLQU1a #PonleFecha

[Leukos Biotech @LeukosBiotech]

LK-01 Granted Orphan Drug Designation by the U.S. FDA for Acute Myeloid Leukemia https://t.co/UtcX2a0ZHg

[EIT Health Spain @EIT_Health_es]

We want to give a very warm welcome as a new @EIT_Health_es partner to Genesis Biomed, a company specialized in providing consulting services to spin-off and start-up companies, entrepreneurs and research centres.

🗞️ Read the new at https://t.co/SSFlIEcaMa

[Leukos Biotech @LeukosBiotech]

LK-01 Granted Orphan Drug Designation by the U.S. FDA for Acute Myeloid Leukemia https://t.co/UtcX2a0ZHg

[Leukos Biotech @LeukosBiotech]

We are hiring!
https://t.co/ZKaN6D23hj

[Leukos Biotech @LeukosBiotech]

We are hiring!
https://t.co/ZKaN6D23hj

[STAT-Dx @STATDx]

QIAGEN enters into agreement to acquire STAT-Dx, plans to launch a next-generation, fully integrated multiplex platform for syndromic disease testing in second half 2018 in Europe and later in the U.S.

[Leukos Biotech @LeukosBiotech]

We are very happy and proud! Our CSO, Dr. Ruth M. Risueño, received an accessit prize from the REAL ACADEMIA NACIONAL DE FARMACIA @RANFarmacia.

[Leukos Biotech @LeukosBiotech]

Great news! Did you know that Leukos Biotech has developed a similar test for Acute Myeloid Leukaemia? https://t.co/fyPnJLYyGH

[nature @Nature]

Simple blood test detects eight different kinds of cancer https://t.co/V3GjBkftXE

[Josep Lluís Falcó @Josep_Falco]

⌛️🔜 #JornadaGENESISBiomed2017 en @PCB_UB. Hablaremos de tendencias en emprendimiento #biofarma con @CaixaCR, Peptomyc, AptaTargets y @LeukosBiotech https://t.co/IuOcE3kXet

[Leukos Biotech @LeukosBiotech]

Leukos Biotech is certified as Innovative SME https://t.co/Q6LxWxjLhw

[Catalonia.Health @CataloniaHealth]

Bé, bé, bé. L'equip Spherium Biomed comença a preparar la barbacoa! #CataloniaBioBBQ @specipig

[Leukos Biotech @LeukosBiotech]

Save the date.
Barcelona Peptide Therapeutics Symposium 2017, 20th September.

[Leukos Biotech @LeukosBiotech]

Meet the CEO of Minoryx, the Spanish Biotech Fighting Rare Disease https://t.co/j8k6QT5kiE